IFT27: A Protein Involved in Multiple Cellular Processes and Potential Drug Targets

Target Name: IFT27

NCBI ID: G11020

IFT27

IFT27: A Protein Involved in Multiple Cellular Processes and Potential Drug Targets

IFT27 (BBS19) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and lungs. It is a member of the Integrin alpha-2 (IAA) family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. IFT27 has been shown to be involved in several cellular processes, including cell adhesion, migration, and invasion.

One of the most promising aspects of IFT27 is its potential as a drug target. IFT27 has been shown to be involved in several diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune diseases. Its unique structure and subcellular localization have made it an attractive target for small molecule inhibitors.

IFT27 has been shown to be involved in several cellular processes that are crucial for normal cell function. One of the most well-studied functions of IFT27 is its role in cell adhesion. IFT27 is a critical protein for the formation of tight junctions, which are essential for maintaining the integrity of the intercellular space and for ensuring the proper delivery of nutrients and toxins to cells.

IFT27 has also been shown to be involved in cell migration and invasion. IFT27 has been shown to be a critical regulator of the migration of cancer cells and has been used as a target for several anti-cancer drugs. In addition, IFT27 has also been shown to be involved in the invasive properties of cancer cells.

IFT27 has also been shown to be involved in several neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroinclusions. IFT27 has been shown to be involved in the development and progression of these conditions, making it an attractive target for new therapies.

In addition to its role in disease, IFT27 has also been shown to be a potential biomarker for several diseases. Its expression has been shown to be altered in a variety of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This makes IFT27 a promising target for the development of diagnostic tools and therapies for these conditions.

In conclusion, IFT27 is a protein that has been shown to be involved in several critical cellular processes that are crucial for normal cell function. Its unique structure and subcellular localization have made it an attractive target for small molecule inhibitors. IFT27 has also been shown to be involved in several diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune diseases. Its potential as a drug target and biomarker make it an attractive target for new therapies. Further research is needed to fully understand the role of IFT27 in these conditions and to develop effective treatments.

Protein Name: Intraflagellar Transport 27

Functions: Small GTPase-like component of the intraflagellar transport (IFT) complex B that promotes the exit of the BBSome complex from cilia via its interaction with ARL6 (PubMed:25443296). Not involved in entry of the BBSome complex into cilium. Prevents aggregation of GTP-free ARL6 (PubMed:25443296). Required for hedgehog signaling. Forms a subcomplex within the IFT complex B with IFT25. Its role in intraflagellar transport is mainly seen in tissues rich in ciliated cells such as kidney and testis. Essential for male fertility, spermiogenesis and sperm flagella formation. Plays a role in the early development of the kidney. May be involved in the regulation of ureteric bud initiation (By similarity)

The "IFT27 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT27 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets